Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 19 | 788 | 46% |
| 2020 | 15 | 622 | 48% |
| 2021 | 15 | 646 | 51% |
| 2022 | 17 | 643 | 53% |
| 2023 | 18 | 558 | 55% |
| 2024 | 12 | 563 | 57% |
| 2025 from claims | – | 537 435–631 | 58% |
| 2026 forecast | – | 543 425–682 | 58% |
| 2027 forecast | – | 546 405–721 | 59% |
| 2028 forecast | – | 549 388–757 | 59% |
| 2029 forecast | – | 551 375–791 | 60% |
| 2030 forecast | – | 554 363–822 | 60% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 89% of the cases CMS names in New York; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 8% inpatient hospital, 76% hospital outpatient, 16% surgery center. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~540 | ~45 | ~410 | ~93 |
| 2027 · ~550 | ~45 | ~400 | ~97 |
| 2028 · ~550 | ~45 | ~400 | ~99 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 18% (16% in 2025), hospital outpatient about 74% (76% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 32 | 1,028−1.4%/yr | −1.4%/yr | 0.7 | 32% | 980 in 2030−0.7%/yr |
| New Jersey | 12 | 392−5%/yr | −5%/yr | 0.4 | 70% | 450 in 2030+2.2%/yr |
| Massachusetts | 5 | 264−7.2%/yr | −7.2%/yr | 0.3 | 15% | 380 in 2030+6.4%/yr |
| New Hampshire | 2 | 101+2.3%/yr | +2.3%/yr | 0.4 | 46% | 190 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 223 | 14,264−0.1%/yr | −0.1%/yr | 7.51.0× | 81% | 18,300 in 2030+4.2%/yr |
| Peripheral nerve stimulation & intrathecal pumps | 22 | 1,267+7.6%/yr | +7.6%/yr | 0.60.9× | 39% | 2,170 in 2030+9.4%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Abbott leads with 24% of company spending on these surgeons in 2025, level with 2024.
In 2025, 11 companies reported engagement with New York’s surgeons worth $1.2M in consulting, speaking, meals and travel tied to these products, about $101K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 631 neurostimulator leads and generators stays at 13 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is MOUNT SINAI WEST (42% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| MOUNT SINAI WEST NEW YORK | 156 | 54% | 42% |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 109 | 43% | 38% |
| NYU LANGONE HOSPITALS NEW YORK | 107 | 44% | 35% |
| NORTH SHORE UNIVERSITY HOSPITAL MANHASSET | 47 | 57% | — |
| WESTCHESTER MEDICAL CENTER VALHALLA | 40 | 50% | — |
| ALBANY MEDICAL CENTER HOSPITAL ALBANY | 36 | — | — |
| STRONG MEMORIAL HOSPITAL ROCHESTER | 32 | 56% | — |
| KALEIDA HEALTH BUFFALO | 26 | — | — |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (Neurostimulator leads and generators: brain and spinal cord stimulators together.). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.